Skip to main content
. Author manuscript; available in PMC: 2009 Jun 4.
Published in final edited form as: Stroke. 2008 Dec 4;40(5):1864–1869. doi: 10.1161/STROKEAHA.108.536680

Figure 4.

Figure 4

Reduced neuroprotection and risk for bleeding with drotrecogin-alfa activated compared with 3K3A-APC mutant after transient MCAO. Vehicle, drotrecogin-α (0.5 and 2 mg/kg) and 3K3A-APC (0.4 and 2 mg/kg) were administered through the femoral vein 5 minutes before 1 hour MCAO. Neuropathological analysis, neurological motor score, and hemoglobin levels were determined at 24 hours of reperfusion. A, Infarct volume. B, Brain swelling (edema). C, Motor neurological score. D, Hemoglobin levels in ischemic hemisphere. Mean ± SEM, n=6 mice per group.